 | Up a level |
Vavricka, Stephan R; Schoepfer, Alain M; Bansky, Georg; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Scharl, Michael; Seibold, Frank; Straumann, Alex; Michetti, Pierre; Swiss, IBDnet (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory bowel diseases, 17(7), pp. 1530-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21521
Schoepfer, Alain M.; Vavricka, Stephan R.; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Seibold, Frank; Straumann, Alex; Michetti, Pierre (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohnʼs disease population. Inflammatory bowel diseases, 16(6), pp. 933-938. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21127
Juillerat, Pascal; Pittet, Valérie; Vader, John-Paul; Burnand, Bernard; Gonvers, Jean-Jacques; de Saussure, Philippe; Mottet, Christian; Seibold, Frank; Rogler, Gerhard; Sagmeister, Markus; Felley, Christian; Michetti, Pierre; Froehlich, Florian; Swiss IBD Cohort Study Group, The (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European journal of gastroenterology & hepatology, 22(11), pp. 1352-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/MEG.0b013e32833eaa8a
